Science Stories
Extensive-stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy. Maintenance therapy may turn the period of stability after their first treatment into an opportunity to extend response and delay relapse.
We strive to put patient priorities first in our research, advancing our understanding of sleep conditions and the needs of those with narcolepsy and idiopathic hypersomnia.
People with sleep conditions, such as narcolepsy and idiopathic hypersomnia, have an increased prevalence of cardiovascular comorbidities compared to people without these sleep conditions. At Jazz, we aim to raise awareness of these connections through our research and partnerships with the goal of providing patients and healthcare providers with meaningful insights that can impact their lives.
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.